Bulan Keziban, Aydogan Metin, Siraneci Rengin, Aydogmus Cigdem Yilmaz
Bakirkoy Maternity and Children's Education and Research Hospital, Istanbul, Turkey.
Int J Pediatr Otorhinolaryngol. 2013 Oct;77(10):1655-8. doi: 10.1016/j.ijporl.2013.07.019. Epub 2013 Aug 1.
It is well-known that number of drugs may interfere with wheal reactions in skin prick test. However, the effect of long-term use of montelukast, a cystenil leukotriene receptor antagonist, on skin prick test hasn't been full elucidated. The aim of present study was to demonstrate the effect of montelukast on skin prick tests (SPT).
This is a single-center, randomized, double-blinded, placebo-controlled study including two treatment periods with a wash-out interval. The subjects received montelukast (5 mg per day), fexofenadine HCl (60 mg per day) and placebo (lactose) with a double-blinded manner during 7- and 21-days treatment periods with a 14 days wash-out period. Dermatophagoides farinae (D. farinae) was used as the skin test material, while histamine as positive control and normal saline as negative control. Overall, 7 skin prick tests were performed at following time points: before treatment periods, on the last days of both treatment periods, 24 h after completion of treatment periods, and on the last day of 14-days interval.
Sixty house dust mite (HDM) allergic children (23 girls and 37 boys) with allergic rhinitis and/or asthma completed the study. Mean age was 8.3 ± 2.0 years. In the fexofenadine group, a significant suppression was observed in post-treatment values when compared to baseline values in SPT with D. farinae (p = 0.019). In the montelukast group, no significant suppression was observed in SPT with D. farinae at all time points when compared to baseline.
Our results showed that montelukast had no effect on measurements of SPT. Thus, we concluded that there is no need to discontinue the treatment in order to perform SPT in patients receiving montelukast, even in those on montelukast treatment for at least 21 days.
众所周知，多种药物可能会干扰皮肤点刺试验中的风团反应。然而，长期使用半胱氨酰白三烯受体拮抗剂孟鲁司特对皮肤点刺试验的影响尚未完全阐明。本研究的目的是证明孟鲁司特对皮肤点刺试验（SPT）的影响。
这是一项单中心、随机、双盲、安慰剂对照研究，包括两个治疗期及一个洗脱期。受试者在为期7天和21天的治疗期内以双盲方式接受孟鲁司特（每日5毫克）、盐酸非索非那定（每日60毫克）和安慰剂（乳糖）治疗，洗脱期为14天。以粉尘螨作为皮肤试验材料，组胺作为阳性对照，生理盐水作为阴性对照。总共在以下时间点进行7次皮肤点刺试验：治疗期前、两个治疗期的最后一天、治疗期结束后24小时以及14天间隔期的最后一天。
60名患有过敏性鼻炎和/或哮喘的屋尘螨（HDM）过敏儿童（23名女孩和37名男孩）完成了研究。平均年龄为8.3±2.0岁。在非索非那定组中，与粉尘螨皮肤点刺试验的基线值相比，治疗后的值有显著降低（p = 0.019）。在孟鲁司特组中，与基线相比，在所有时间点的粉尘螨皮肤点刺试验中均未观察到显著降低。
我们的结果表明孟鲁司特对皮肤点刺试验的测量没有影响。因此，我们得出结论，接受孟鲁司特治疗的患者无需为了进行皮肤点刺试验而停药，即使是那些接受孟鲁司特治疗至少21天的患者。
